^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Bylantra (devimistat) (PDH inhibitor, α-KGDH inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
Published date:
12/15/2020
Excerpt:
Rafael Pharmaceuticals, Inc...a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead compound, CPI-613® (devimistat), for the treatment of acute myeloid leukemia (AML).
